Clinical protocol for early treatment of COVID-19 in a real-world scenario: Results of a series of patients
Sobrinho et al.,
Clinical protocol for early treatment of COVID-19 in a real-world scenario: Results of a series of patients,
Medicina Clínica Práctica, doi:10.1016/j.mcpsp.2022.100346
Retrospective 116 patients between May and September 2020 in Brazil receiving an early treatment protocol including ivermectin and azithromycin, showing no mortality compared to up to 5.7% CFR in Brazil during the study period.
Sobrinho et al., 22 Sep 2022, Brazil, peer-reviewed, mean age 48.0, 4 authors, study period May 2020 - September 2020.
Abstract: Medicina Clínica Práctica 5 (2022) 100346
www.elsevier.es/medicinaclinicapractica
Original
Clinical protocol for early treatment of COVID-19 in a real-world
scenario: Results of a series of patients
Silvestre Sobrinho a,⁎, Fabiana Perrone a, Guilherme Montal b, Aroldo Bacellarc
a
b
c
Department of Internal Medicine and Emergency Service, Hospital da Cidade, Salvador, BA, Brazil
University Hospital Prof. Edgard Santos, Salvador, Brazil
Monte Tabor Foundation, Hospital São Rafael, Salvador, Brazil
a r t i c l e in f o
a b s t r a c t
Article history:
Received 10 July 2022
Accepted 11 September 2022
Available online 22 September 2022
Introduction: Despite the advance in vaccination, the SARS-CoV-2 infection remains a challenge for the medical
community. Outpatient and hospital therapy for COVID-19 are still improving. Our study aimed to report the
results of a series of patients with COVID-19 who participated in an outpatient treatment protocol since the
first clinical manifestation.
Methods: A case series report of individuals aged ≥18 years with clinical symptoms and a confirmed test for
COVID-19 submitted to a treatment protocol. Patients were enrolled between May and September 2020 and
followed for at least 15 days. The assessed clinical outcomes were the need for hospitalization, admission to
the intensive care unit, orotracheal intubation, and death.
Results: We studied a 116 patients. The mean age was 48 ± 14 years. Females formed 53%. The main comorbidities wereobesity (15.5%), systemic arterial hypertension (10.3%) ,type II diabetes (6%), and lung diseases (6.0%).
Temperature N 37.7 °C (51.7%), cough (55.2%), myalgia (37.1%), headache (37.9%), and fatigue (34.5%) were the
most frequent signs and symptoms. According to different disease staging, the most administered drugs were:
azithromycin, ivermectin, corticosteroid, antibiotics, and anticoagulants. There was no death, and hospitalization
accounted for only 8.6% of the patients (1 in ICU); none required orotracheal intubation. The mean length of
hospital stay was 5.8 days.
© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the license CC BY-NC-ND (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords:
COVID-19
Treatment protocol
Ivermectin
Corticosteroid
Anticoagulant
Protocolo Clínico para el Tratamiento Precoz de la COVID-19 en un escenario real:
resultados de una serie de pacientes
r e s u m e n
Palabras clave:
COVID -19
Protocolo de tratamiento
Ivermectina
corticoide
anticoagulanteducción
Introducción: a pesar del avance en la vacunación, la infección por SARS-CoV-2 sigue siendo un desafío para la
comunidad médica. La terapia ambulatoria y hospitalaria para COVID-19 sigue mejorando. Nuestro estudio
tuvo como objetivo informar los resultados de una serie de pacientes con COVID-19 que participaron en un
protocolo de tratamiento ambulatorio desde la primera manifestación clínica.
Métodos: estudio prospectivo con reportes de casos de personas ≥ 18 años con síntomas clínicos y pruebas
confirmadas de COVID-19 en protocolo de tratamiento. Los pacientes se trataron consecutivamente entre
mayo y septiembre de 2020 y se les dio seguimiento durante al menos 15 días. Los desenlaces clínicos evaluados
fueron: la necesidad de hospitalización, la unidad de cuidados intensivos, la intubación orotraqueal y la muerte.
Resultados: se estudiaron 116 pacientes. La edad media fue de 48 ± 14 años. Las hembras formaron el 53%. Las
principales..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit